Clarity Pharmaceuticals (ASX:CU6) Other Operating Expense: A$5.08 Mil (TTM As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.41
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Other Operating Expense?

Clarity Pharmaceuticals ASX:CU6 +1.69% 39 Other Operating Expense is A$5.08 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's Other Operating Expense for the six months ended in Dec. 2025 was A$2.67 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.08 Mil.

Clarity Pharmaceuticals's quarterly Other Operating Expense declined from Dec. 2024 (A$3.09 Mil) to Jun. 2025 (A$2.41 Mil) but then increased from Jun. 2025 (A$2.41 Mil) to Dec. 2025 (A$2.67 Mil).

Clarity Pharmaceuticals's annual Other Operating Expense increased from Jun. 2023 (A$2.68 Mil) to Jun. 2024 (A$5.05 Mil) and increased from Jun. 2024 (A$5.05 Mil) to Jun. 2025 (A$5.50 Mil).

Clarity Pharmaceuticals Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Other Operating Expense Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Operating Expense
2.32 2.68 5.05 5.50

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 2.85 3.09 2.41 2.67
ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$5.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of A$5.08 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Other Operating Expense of A$5.08 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Other Operating Expense too high?
Clarity Pharmaceuticals' current Other Operating Expense is A$5.08 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Other Operating Expense compare to VRTX and REGN?
Clarity Pharmaceuticals' Other Operating Expense of A$5.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Other Operating Expense is A$5.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Other Operating Expense of A$5.08 Mil. The current Other Operating Expense is A$5.08 Mil. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Other Operating Expense is A$5.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.41
Price